Rhythm Pharmaceuticals ( (RYTM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Pharmaceuticals shares came under pressure after trading was halted and then resumed following disappointing results from its EMANATE Phase 3 trial. The setback raised doubts about near‑term growth drivers and triggered a reassessment of the company’s prospects by Wall Street.
Several analysts cut their price targets and stripped out expected sales from the SRC1 and SH2B1 programs in their models. Even so, many kept Buy ratings, pointing to the validated MC4R mechanism, an upcoming PDUFA decision, and broader pipeline potential as reasons for longer‑term optimism.
More about Rhythm Pharmaceuticals
YTD Price Performance: -19.79%
Average Trading Volume: 710,462
Technical Sentiment Signal: Hold
Current Market Cap: $5.86B
For further insights into RYTM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.